FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Sci / Hematological and Biochemical Effects Associated with Prolon...
Veterinary sciences2024; 11(6); doi: 10.3390/vetsci11060256

Hematological and Biochemical Effects Associated with Prolonged Administration of the NSAID Firocoxib in Adult Healthy Horses.

Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most commonly used classes of drugs in both human and veterinary medicine. However, many clinical side effects have been observed, especially when treatment has been prolonged. While the anti-inflammatory efficacy and safety of repeated administration of firocoxib (Previcox®), which is a selective NSAID COX-2 inhibitor, has been evaluated for short-term use (one to fourteen days), its clinical relevance for longer-term use is not known. As a preliminary study, healthy, adult male and female horses (n = 7) were treated with firocoxib for 40 days concomitant with the collection of blood samples encompassing treatment to assess hematological and biochemical endpoints. Daily oral administration of firocoxib was performed with one 57 mg tablet/animal (0.11-0.14 mg/kg), which was crushed and mixed with feed. Blood samples were collected one day before treatment (D0 or basal sample), during (D10, D20, D30, and D40), and after treatment (D55 and D70). Results indicated some hematological and biochemical effects were significantly reduced (p < 0.05) towards the end of treatment on D40 relative to pre-treatment or baseline values on D0. Post-treatment, all values returned to pre-treatment values within 30 days without any apparent clinical adversities. In conclusion, while these preliminary results are favorable for prolonged use of firocoxib in horses, future studies are required to evaluate the efficacy of prolonged use accompanied with other clinically relevant endpoints in healthy as well as injured or diseased animals.
Get Full Text
Publication Date: 2024-06-05 PubMed ID: 38922003PubMed Central: PMC11209463DOI: 10.3390/vetsci11060256Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper studies the impact of prolonged use of a particular non-steroidal anti-inflammatory drug (NSAID), Firocoxib, on healthy adult horses. The study considers both hematological and biochemical aspects for analysis.

Research Background

  • The study focuses on the NSAID Firocoxib, popularly termed Previcox, a COX-2 inhibitor.
  • This drug class is frequently utilized in both human and veterinary medicine.
  • Despite their frequent use, NSAIDs are often associated with potential side-effects, especially upon long-term usage.
  • Firocoxib has been previously assessed for short-term use spanning one to fourteen days.
  • This research aims to understand the impacts of Firocoxib on horses over a prolonged period, pushing beyond the scope of the earlier assessment.

Methods and Procedure

  • The preliminary study involved adult male and female horses (seven in total).
  • These horses were provided with Firocoxib for forty days, alongside regular blood sample collections to monitor hematological and biochemical changes.
  • The horses received one 57 mg Firocoxib tablet per day, crushed and mixed with feed.
  • Blood samples were taken on different days- a day before treatment (D0 or basal sample), during treatment (D10, D20, D30, and D40), and after treatment (D55 and D70).

Results

  • The findings of the study indicated significant reductions (< 0.05) in some hematological and biochemical effects on the fortieth day (D40) relative to initial pre-treatment (baseline) values (D0).
  • All these measurements returned to their pre-treatment values within 30 days after cessation of treatment, with no notable clinical adversities detected.

Conclusion

  • The study’s preliminary results suggest that the long-term use of Firocoxib in horses generally has favorable impacts.
  • However, acknowledging the preliminary nature of this study, the researchers concluded that future research should delve deeper into analyzing the drug’s efficacy on horses over a long duration, considering additional clinical relevant points.
  • This future research should encompass not just healthy animals, but also those that are injured or have certain diseases.

Cite This Article

APA
Ignácio FS, Garcia LV, de Souza GG, Amatti LZ, de Barros LD, Bergfelt DR, Camargo GS, de Meira C, de Almeida BFM. (2024). Hematological and Biochemical Effects Associated with Prolonged Administration of the NSAID Firocoxib in Adult Healthy Horses. Vet Sci, 11(6). https://doi.org/10.3390/vetsci11060256

Publication

Veterinary sciences
ISSN: 2306-7381
NlmUniqueID: 101680127
Country: Switzerland
Language: English
Volume: 11
Issue: 6

Researcher Affiliations

Ignácio, Fernanda Saules
  • Department of Veterinary Surgery and Animal Surgery, School of Veterinary Medicine and Animal Science (FMVZ), Sao Paulo State University (UNESP), Botucatu 18618-681, SP, Brazil.
Garcia, Luana Venâncio
  • Department of Veterinary Medicine, University Center of the Integrated Faculties of Ourinhos (Unifio), Ourinhos 19909-100, SP, Brazil.
de Souza, Giovanna Gati
  • Department of Veterinary Medicine, University Center of the Integrated Faculties of Ourinhos (Unifio), Ourinhos 19909-100, SP, Brazil.
Amatti, Lidiana Zanetti
  • Department of Veterinary Medicine, University Center of the Integrated Faculties of Ourinhos (Unifio), Ourinhos 19909-100, SP, Brazil.
de Barros, Luiz Daniel
  • Laboratory of Veterinary Parasitology and Parasitic Diseases, Department of Veterinary Medicine, Federal University of Lavras, Lavras 37203-202, MG, Brazil.
Bergfelt, Don R
  • Department of Biomedical Science, Ross University School of Veterinary Medicine, Basseterre P.O. Box 334, Saint Kitts and Nevis.
Camargo, Giovana Siqueira
  • Department of Veterinary Surgery and Animal Surgery, School of Veterinary Medicine and Animal Science (FMVZ), Sao Paulo State University (UNESP), Botucatu 18618-681, SP, Brazil.
de Meira, Cezinande
  • Department of Veterinary Surgery and Animal Surgery, School of Veterinary Medicine and Animal Science (FMVZ), Sao Paulo State University (UNESP), Botucatu 18618-681, SP, Brazil.
de Almeida, Breno Fernando Martins
  • Department of Veterinary Medicine, University Center of the Integrated Faculties of Ourinhos (Unifio), Ourinhos 19909-100, SP, Brazil.
  • Departament of Clinics, Surgery and Animal Reproduction, Faculty of Veterinary Medicine of Araçatuba (FMVA), São Paulo State University (UNESP), Araçatuba 16050-680, SP, Brazil.

Grant Funding

  • 2024 / Universidade Estadual Paulista (Unesp)

Conflict of Interest Statement

The authors declare no conflicts of interest.

References

This article includes 47 references
  1. Hovenassian N, Davis JL, McKenzie HC 3rd, Hodgson JL, Hodgson JL, Crisman MV. Pharmacokinetics and safety of firocoxib after oral admnistration of repeated consecutive doses to neonatal foals.. J. Vet. Pharmacol. Ther. 2013;37:243–251.
    doi: 10.1111/jvp.12082pubmed: 24749691google scholar: lookup
  2. Doucet MY, Bertone AL, Hendrickson D, Hughes F, MacAllister C, McClure S, Reinemeyer C, Rossier Y, Sifferman R, Vrins AA. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.. J. Am. Vet. Med. Assoc. 2008;232:91–97.
    doi: 10.2460/javma.232.1.91pubmed: 18167116google scholar: lookup
  3. Campbell NB, Blikslager AT. The role of cyclooxigenase inhibitors in repair of ischaemic-injured jejunal mucosa in the horse.. Equine Vet. J. 2000;32:59–64.
    doi: 10.1111/j.2042-3306.2000.tb05335.xpubmed: 11202384google scholar: lookup
  4. Cook VL, Meyer CT, Campbell NB, Blikslager AT. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum.. Am. J. Vet. Res. 2009;70:992–1000.
    doi: 10.2460/ajvr.70.8.992pubmed: 19645580google scholar: lookup
  5. Holland B, Fogle C, Blikslager AT, Curling A, Barlow BM, Schirmer RJ, Davis JL. Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses.. J. Vet. Pharmacol. Ther. 2014;38:249–256.
    doi: 10.1111/jvp.12177pubmed: 25378135google scholar: lookup
  6. Rangel-Nava A, Ramírez-Uribe JM, Recillas-Morales S, Ibancovichi-Camarillo JA, Venebra-Muñoz A, Sánchez-Aparicio P. Pharmacological regulation in the USA and pharmacokinetics parameters of firocoxib, a highly selective cox-2, by pain management in horses.. J. Equine Vet. Sci. 2019;77:36–42.
    doi: 10.1016/j.jevs.2019.02.007pubmed: 31133314google scholar: lookup
  7. Barton MH, Paske E, Norton N, King D, Giguère S, Budsberg S. Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses.. Equine Vet. J. 2014;46:72–75.
    doi: 10.1111/evj.12095pmc: PMC3805772pubmed: 23662599google scholar: lookup
  8. Macpherson ML, Giguère S, Pozor MA, Burden CA, Berghaus LJ, Berghaus RD, Varner JC, Hayna JT, Benson SM, Randell SA. Evidence for anti-inflammatory effects of firocoxib administered to mares with experimentally induced placentitis.. Am. J. Reprod. Immunol. 2021;86:e13396.
    doi: 10.1111/aji.13396pubmed: 33569862google scholar: lookup
  9. Friso AM, Segabinazzi LGT, Cyrino M, Correal SB, Freitas-Dell’Aqua CP, Carmo MT, Dell’Aqua JA, Miró J, Papa FO, Alvarenga MA. Periovulatory administration of firocoxib did not alter ovulation rates and mitigated post-breeding inflammatory response in mares.. Theriogenology 2019;138:24–30.
    doi: 10.1016/j.theriogenology.2019.06.045pubmed: 31280182google scholar: lookup
  10. Traub JL, Gallina AM, Grant BD, Reed SM, Gavin PR, Paulsen LM. Phenylbutazone toxicosis in the foal.. Am. J. Vet. Res. 1983;44:1410–1418.
    pubmed: 6625291
  11. Traub-Dargatz JL, Bertone JJ, Gould DH, Wrigley RH, Weiser MG, Forney SD. Chronic flunixin meglumine therapy in foals.. Am. J. Vet. Res. 1988;49:7–12.
    pubmed: 3354970
  12. Wilson KE, Davis JL, Crisman MV, Kvaternick V, Zarabadipour C, Cheramie H, Hodgson DR. Pharmacokinetics of firocoxib after intravenous administration of multiple consecutive doses in neonatal foals.. J. Vet. Pharmacol. Ther. 2017;40:23–29.
    doi: 10.1111/jvp.12410pubmed: 28456000google scholar: lookup
  13. Everts B, Wahrborg P, Hedner T. COX-2- specific inhibitors—The emergence of a new class of analgesic and anti-inflammatory drugs.. Clin. Rheumatol. 2000;19:331–343.
    doi: 10.1007/s100670070024pubmed: 11055820google scholar: lookup
  14. Little D, Jones SL, Blikslager AT. Cyclooxygenase (COX) inhibitors and the intestine.. J. Vet. Intern. Med. 2007;21:367–377.
    doi: 10.1892/0891-6640(2007)21[367:cciati]2.0.co;2pubmed: 17552439google scholar: lookup
  15. Cox S, Dudenbostel L, Sommardahl C, Yarbrough J, Saleh M, Doherty T. Pharmacokinetics of firocoxib and its interaction with enrofloxacin in horses.. J. Vet. Pharmacol. Ther. 2012;35:615–617.
    doi: 10.1111/j.1365-2885.2011.01362.xpubmed: 22233122google scholar: lookup
  16. Cox S, Villarino N, Sommardahl C, Kvaternick V, Zarabadipour C, Siger L, Yarbrough J, Amicucci A, Reed K, Breeding D. Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen.. Vet. J. 2013;198:382–385.
    doi: 10.1016/j.tvjl.2013.07.035pubmed: 24076125google scholar: lookup
  17. Donnel JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis.. Vet. Med. Res. Rep. 2014;5:159–168.
    doi: 10.2147/VMRR.S70207pmc: PMC7337192pubmed: 32670856google scholar: lookup
  18. Knych HK, Stanley SD, Arthur RM, Mitchell MM. Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses.. Equine Vet. J. 2014;46:734–738.
    doi: 10.1111/evj.12211pubmed: 24393414google scholar: lookup
  19. Letendre LT, Tessman RK, McClure SR, Kvaternick VJ, Fischer JB, Hanson PD. Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses.. Am. J. Vet. Res. 2008;69:1399–1405.
    doi: 10.2460/ajvr.69.11.1399pubmed: 18980421google scholar: lookup
  20. Armstrong DT. Prostaglandins and follicular functions.. J. Reprod. Fertil. 1981;62:283–291.
    doi: 10.1530/jrf.0.0620283pubmed: 6262509google scholar: lookup
  21. Fitzpatrick FA. Cyclooxygenase enzymes: Regulation and function.. Curr. Pharm. Des. 2004;10:577–588.
    doi: 10.2174/1381612043453144pubmed: 14965321google scholar: lookup
  22. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs.. Am. J. Vet. Res. 2004;65:810–818.
    doi: 10.2460/ajvr.2004.65.810pubmed: 15198222google scholar: lookup
  23. Wallace JL, Reuter BK, McKnight W, Bak A. Selective inhibitors of cyclooxygenase-2: Are they really effective, selective, and GI-safe?. J. Clin. Gastroenterol. 1998;27((Suppl. S1)):S28–S34.
    doi: 10.1097/00004836-199800001-00006pubmed: 9872495google scholar: lookup
  24. Zimmermann KC, Sarbia M, Schrör K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa.. Mol. Pharmacol. 1998;54:536–540.
    doi: 10.1124/mol.54.3.536pubmed: 9730912google scholar: lookup
  25. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.. N. Engl. J. Med. 1999;44:1888–1899.
    doi: 10.1056/NEJM199906173402407pubmed: 10369853google scholar: lookup
  26. Gilroy DW, Colville-Nash PR. New insights into the role of COX 2 in inflammation.. J. Mol. Med. 2000;78:121–129.
    doi: 10.1007/s001090000094pubmed: 10868474google scholar: lookup
  27. MacNaughton WK, Cushing K. Role of constitutive cyclooxygenase-2 in prostaglandin-dependent secretion in mouse colon in vitro.. J. Pharmacol. Exp. Ther. 2000;293:539–544.
    pubmed: 10773026
  28. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D, Ptak A, Hahn EG. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.. Microsc. Res. Tech. 2001;53:343–353.
    doi: 10.1002/jemt.1102pubmed: 11376495google scholar: lookup
  29. Einhorn TA. Cox-2: Where are we in 2003?—The role of cyclooxygenase-2 in bone repair.. Arthritis Res. Ther. 2003;5:5–7.
    doi: 10.1186/ar607pmc: PMC154427pubmed: 12716441google scholar: lookup
  30. Warner TD, Mitchell JA. Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic.. FASEB J. 2004;18:790–804.
    doi: 10.1096/fj.03-0645revpubmed: 15117884google scholar: lookup
  31. Brzozowska I, Targosz A, Sliwowski Z, Kwiecien S, Drozdowicz D, Pajdo R, Konturek PC, Brzozowski T, Paslik M, Konturek SJ. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor.. J. Physiol. Pharmacol. 2004;55:773–790.
    pubmed: 15613743
  32. Fumuso EA, Aguilar J, Giguère S, Rivulgo M, Wade J, Rogan D. Immune parameters in mares resistant and susceptible to persistent post-breeding endometritis: Effects of immunomodulation.. Vet. Immunol. Immunopathol. 2007;118:30–39.
    doi: 10.1016/j.vetimm.2007.04.009pubmed: 17559943google scholar: lookup
  33. Mukhopadhyay N, Shukla A, Mackal PN, Kaki VR. Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents.. Heliyon 2023;9:e14569.
    doi: 10.1016/j.heliyon.2023.e14569pmc: PMC10068128pubmed: 37020932google scholar: lookup
  34. Robinson N, Sprayberry KA. Current Therapy in Equine Medicine.. 6th ed. Saunders Elsevier; St Louis, MI, USA: 2009.
  35. Thrall MA. Hematologia e Bioquímica Clínica Veterinária.. 1st ed. Rocca; São Paulo, Brazil: 2007.
  36. Kaneko JJ, Harvey JW, Bruss ML. Clinical Biochemistry of Domestic Animals.. 6th ed. Academic Press Inc.; Cambridge, MA, USA: 2008.
  37. Mozaffari AA, Derakhshanfar A, Alinejad A, Morovati M. A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: Haematological, biochemical and pathological findings.. N. Z. Vet. J. 2010;58:224–228.
    doi: 10.1080/00480169.2010.69295pubmed: 20927172google scholar: lookup
  38. Knych HK. Nonsteroidal anti-inflammatory drug use in horses.. Vet. Clin. Equine. 2017;33:1–15.
    doi: 10.1016/j.cveq.2016.11.001pubmed: 28190614google scholar: lookup
  39. Flood J, Stewart AJ. Non-steroidal anti-inflammatory drugs and associated toxicitied in horses.. Animals 2022;12:2939.
    doi: 10.3390/ani12212939pmc: PMC9655344pubmed: 36359062google scholar: lookup
  40. Aranzales JRM, Andrade BSC, Alves GES. Orally administered phenylbutazone causes oxidative stress in the equine gastric mucosa.. J. Vet. Pharmacol. Therap. 2014;38:257–264.
    doi: 10.1111/jvp.12168pubmed: 25287371google scholar: lookup
  41. Orsini JA, Ryan WG, Carithers DS, Boston RC. Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses.. Am. J. Vet. Res. 2012;73:664–667.
    doi: 10.2460/ajvr.73.5.664pubmed: 22533398google scholar: lookup
  42. Mac Allister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses.. JAVMA 1993;202:71–77.
    doi: 10.2460/javma.1993.202.01.71pubmed: 8420909google scholar: lookup
  43. FDA. U.S. Food and Drug Administration Transdermal Drug.. [(accessed on 18 November 2022)]; Available online: https://www.fda.gov/animal-veterinary.
  44. Tyler RD, Cowell RL, Clinkenbeard KD, MacAllister CG. Hematologic values in horse and interpretation of hematologic data.. Vet. Clin. N. Am. Equine Pract. 1987;3:461–484.
    doi: 10.1016/s0749-0739(17)30659-4pubmed: 3322521google scholar: lookup
  45. Boelsterli UA. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity.. Toxicol. Appl. Pharmacol. 2003;192:307–322.
    doi: 10.1016/s0041-008x(03)00368-5pubmed: 14575648google scholar: lookup
  46. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs.. Annu. Rev. Pharmacol. Toxicol. 1993;33:435–465.
    doi: 10.1146/annurev.pa.33.040193.002251pubmed: 8494347google scholar: lookup
  47. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflamatory drugs (NSAIDs) and organ damage: A current perspective.. Biochem. Pharmacol. 2020;180:114–147.
    doi: 10.1016/j.bcp.2020.114147pmc: PMC7347500pubmed: 32653589google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.